LU500644B1 - Drug combination, preparation and application for treating coronary heart disease - Google Patents
Drug combination, preparation and application for treating coronary heart disease Download PDFInfo
- Publication number
- LU500644B1 LU500644B1 LU500644A LU500644A LU500644B1 LU 500644 B1 LU500644 B1 LU 500644B1 LU 500644 A LU500644 A LU 500644A LU 500644 A LU500644 A LU 500644A LU 500644 B1 LU500644 B1 LU 500644B1
- Authority
- LU
- Luxembourg
- Prior art keywords
- heart disease
- coronary artery
- parts
- weight
- pharmaceutical composition
- Prior art date
Links
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 239000000890 drug combination Substances 0.000 title description 2
- 201000000057 Coronary Stenosis Diseases 0.000 claims abstract description 49
- 206010011089 Coronary artery stenosis Diseases 0.000 claims abstract description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 39
- 239000004475 Arginine Substances 0.000 claims abstract description 27
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 27
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 27
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 27
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 27
- 229940110767 coenzyme Q10 Drugs 0.000 claims abstract description 27
- 239000000395 magnesium oxide Substances 0.000 claims abstract description 20
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims abstract description 20
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims abstract description 20
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical class C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 15
- ZFLASALABLFSNM-QBOHGLHMSA-L carbanide;cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-oc Chemical compound [CH3-].[Co+3].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ZFLASALABLFSNM-QBOHGLHMSA-L 0.000 claims abstract description 14
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims description 52
- 238000003756 stirring Methods 0.000 claims description 32
- 239000003814 drug Substances 0.000 claims description 27
- 229940079593 drug Drugs 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 17
- 239000002245 particle Substances 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 229930003270 Vitamin B Natural products 0.000 claims description 2
- 235000019156 vitamin B Nutrition 0.000 claims description 2
- 239000011720 vitamin B Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 14
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract description 8
- 230000002107 myocardial effect Effects 0.000 abstract description 7
- 230000002537 thrombolytic effect Effects 0.000 abstract description 7
- 208000007536 Thrombosis Diseases 0.000 abstract description 6
- 230000003902 lesion Effects 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 abstract description 4
- 238000003384 imaging method Methods 0.000 abstract description 4
- 230000002757 inflammatory effect Effects 0.000 abstract description 4
- 230000007547 defect Effects 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 2
- 238000004393 prognosis Methods 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 210000004351 coronary vessel Anatomy 0.000 description 23
- 230000015572 biosynthetic process Effects 0.000 description 20
- 210000002889 endothelial cell Anatomy 0.000 description 17
- 208000031481 Pathologic Constriction Diseases 0.000 description 16
- 230000036262 stenosis Effects 0.000 description 16
- 208000037804 stenosis Diseases 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 15
- 208000004434 Calcinosis Diseases 0.000 description 9
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 9
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 9
- 208000010125 myocardial infarction Diseases 0.000 description 9
- 235000019163 vitamin B12 Nutrition 0.000 description 9
- 239000011715 vitamin B12 Substances 0.000 description 9
- ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical compound C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 description 8
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 8
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 8
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 8
- 230000002308 calcification Effects 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 229960003208 levomefolic acid Drugs 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000007505 plaque formation Effects 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 5
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 5
- 206010035148 Plague Diseases 0.000 description 5
- 241000607479 Yersinia pestis Species 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000004064 dysfunction Effects 0.000 description 5
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- 230000003511 endothelial effect Effects 0.000 description 5
- 102000006538 Nitric Oxide Synthase Type I Human genes 0.000 description 4
- 108010008858 Nitric Oxide Synthase Type I Proteins 0.000 description 4
- 229930003779 Vitamin B12 Natural products 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 229940064128 l-methylfolate Drugs 0.000 description 4
- 235000007635 levomefolic acid Nutrition 0.000 description 4
- 239000011578 levomefolic acid Substances 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000019553 vascular disease Diseases 0.000 description 4
- 206010048554 Endothelial dysfunction Diseases 0.000 description 3
- 102000020897 Formins Human genes 0.000 description 3
- 108091022623 Formins Proteins 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000008280 blood Chemical class 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000008694 endothelial dysfunction Effects 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229910001425 magnesium ion Inorganic materials 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N para-benzoquinone Natural products O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940039231 contrast media Drugs 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000254 damaging effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 229940014144 folate Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- -1 methyl vitamin Chemical class 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 206010054211 Cardiac discomfort Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000998969 Homo sapiens Inositol-3-phosphate synthase 1 Proteins 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100036881 Inositol-3-phosphate synthase 1 Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- YDGMGEXADBMOMJ-LURJTMIESA-N N(g)-dimethylarginine Chemical compound CN(C)C(\N)=N\CCC[C@H](N)C(O)=O YDGMGEXADBMOMJ-LURJTMIESA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 102100031887 Nanos homolog 1 Human genes 0.000 description 1
- 101710196788 Nanos homolog 1 Proteins 0.000 description 1
- 102100031892 Nanos homolog 2 Human genes 0.000 description 1
- 101710196785 Nanos homolog 2 Proteins 0.000 description 1
- 102100031893 Nanos homolog 3 Human genes 0.000 description 1
- 101710196784 Nanos homolog 3 Proteins 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000005475 Vascular calcification Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 208000006170 carotid stenosis Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 229940030842 coenzyme Q10 150 mg Drugs 0.000 description 1
- 229940019910 coenzyme Q10 200 mg Drugs 0.000 description 1
- 229940068012 coenzyme Q10 300 mg Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000003225 hyperhomocysteinemia Effects 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229940064321 magnesium oxide 100 mg Drugs 0.000 description 1
- 229940033274 magnesium oxide 200 mg Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940020573 plavix Drugs 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000004647 pro-inflammatory pathway Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention involves a pharmaceutical composition for treating coronary artery stenosis of coronary heart disease, its preparation method and application. The pharmaceutical composition for treating coronary artery stenosis of coronary heart disease is composed of L- methyl folate salt, coenzyme Q10, methyl vitamin B12, arginine and magnesium oxide as raw materials and supplemented with appropriate dose ratio. The pharmaceutical composition for the treatment of coronary artery stenosis of coronary heart disease is finally prepared. Various raw material components play a synergistic role in improving the function of vascular endothelial cells, eliminating myocardial cell inflammatory factors, and improving myocardial activity. It can effectively metabolize the formed atherosclerosis, dissolve thrombus by thrombolysis, and directly act on the lesion, so as to achieve the purpose of reversing coronary artery stenosis of coronary heart disease. The invention overcomes the defect that the existing technology cannot obtain the imaging improvement effect, and can well achieve lesion reversal and good prognosis.
Description
DRUG COMBINATION, PREPARATION AND APPLICATION FOR TREATING CORONARY HEART DISEASE 0500644
[0001] The invention belongs to the technical field of medicine, specifically relates to the pharmaceutical composition, preparation method and application for treating coronary artery stenosis of coronary heart disease.
[0002] Coronary heart disease is a heart disease, also known as ischemic heart disease, which is caused by myocardial ischemia, hypoxia (angina) or myocardial necrosis (myocardial infarction) caused by stenosis or obstruction of organic coronary artery (atherosclerosis or dynamic vasospasm). Coronary artery stenosis is caused by thrombus deposition blockage, and the stenosis to a certain extent leads to myocardial infarction, which is myocardial infarction or myocardial infarction.
[0003] Studies have shown that coronary heart disease, myocardial infarction and myocardial infarction are all vascular diseases, which are caused by endothelial cell dysfunction. It is due to the tortuous parts of the physiological structure including cardiovascular and cerebrovascular diseases under the influence of hemodynamics, endothelial cell dysfunction is characterized by lesions. Endothelial cell dysfunction is an important pathological source of many diseases, especially vascular diseases. Coronary heart disease (atherosclerosis) is a vascular disease, a disease of endothelial dysfunction.
[0004] Under physiological conditions, endothelial cells prevent thrombosis by means of different anticoagulant and antiplatelet mechanisms. These cells take part in all major hemostasis pathways triggered during vascular injury and limit blood clot formation to areas requiring hemostasis to restore vascular integrity. As a result of genetic or acquired disorders, this complex breakdown of balance between coagulants and anticoagulant systems can result in bleeding or thrombosis. Endothelial dysfunction not only occurs before the occurrence of atherosclerosis, but also may occur during arterial thrombosis. The above-mentioned conditions are shown in endothelial cells endogenous synthesis and release of NO function. Studies have confirmed that endothelial-derived NO reduction is caused by the endothelial phenotype changes. Based on the above-mentioned theory, NO thrombolysis and thrombosis models were established. In these models, inhibiting endothelial NO production would exacerbate coronary artery lesions, and L- arginine treatment retained vascular morphology.
[0005] In an inflammatory state, due to the increase of C-reactive protein level, atherosclerosis is promoted and endothelial dysfunction occurs. By reducing the stability of eNOS mRNA (endothelial nitric oxide synthase messenger ribonucleic acid), to reduce the production of NO mediated by eNOS (endothelial nitric oxide synthase). What's more, the two mediators of 1 atherosclerosis, oxidized lipoproteins and lysophospholipid choline, inhibit the release of NO and EDHF (endothelial-dependent hyperpolarization factor, an important active substance wit! 200644 vasodilator effect). Oxidized low density lipoprotein can also reduce the expression or function of eNOS, which can be reversed by antioxidants. Lipids and oxidants can also reduce the bioavailability of NO by damaging cytoplasmic membrane microcapsules and activating NFxB (nuclear factor)-mediated pro-inflammatory pathway. At present, the consistent content in the research is that: the above physiological processes mainly lead to a kind of amino acid metabolite called “homocysteine”. The accumulation of homocysteine forms high homocysteine and then forms “hyperhomocysteinemia”. Therefore, it is believed that high homocysteine is an independent risk factor for vascular diseases such as stroke and myocardial infarction.
[0006] Based on the above theory, the most important dysfunction of endothelial cells is the synthesis and release of NO. The inventor further realizes in clinical practice that the complex enzymatic reaction process activates three kinds of NO synthases to play the role of NO synthesis. The inhibition of asymmetric dimethylarginine (ADMS) on three NO synthases (NOS: neuronal nitric oxide synthase, nNOS, NOS-1; inducible nitric oxide synthase, INOS, NOS-2; endothelial nitric oxide synthase, eNOS, NOS-3) can be reversed by high concentration of L arginine and catalyzed to NO. NOS can produce superoxide anion and uncoupling when the activity of L arginine substrate or other auxiliary factors is deficient. ADMS can also decompose NOS and lead to the production of superoxide (biological characteristics of ADMS). Therefore, endothelial cell function not only has the effect of thrombolysis, thrombolysis and vasodilation, but more importantly, it can also metabolize the formed vascular plague and the physiological garbage deposited in the vascular wall, so as to improve imaging or eliminate vascular occlusion. This is particularly prominent during reversal treatment of coronary stenosis stents.
[0007] NO is the main substance that maintains and ensures the normal work of endothelial cells. NO not only has the effect of dilating blood vessels, but also is an important neurotransmitter with thrombolytic and thrombolytic effects. Arginine is a direct precursor for NO synthesis, a natural maintenance agent and stabilizer for endothelial NO synthase cofactor, and a maintenance substance for endothelial cells. Studies have shown that increasing arginine supply contributes to increase NO production and improve endothelial cell function. That is: it's helpful to cardiovascular and cerebrovascular diseases. Arginine is a semi-essential amino acid, which is prone to deficiency in a certain population and becomes more obvious with age. Endothelial cell NO synthesis is accomplished by endothelial cell NO synthase. Endothelial cell NO synthase activity is closely related to the cofactors of the enzyme, and patients with cardiovascular and cerebrovascular diseases have different degrees of defects in the cofactors of the synthase.
[0008] At present, therapeutic drugs include lowering plasma cholesterol drugs, inhibiting cholesterol absorption, conversion drugs, and anti-hyperlipidemia drugs. The pharmacology of these drugs is to reduce the formation of atherosclerosis by lowering cholesterol or blood lipids without metabolizing the formed atherosclerosis. Clinically, the treatment of coronary heart 2 disease with cholesterol and blood lipids has been proved to be unable to fundamentally eliminate the formation of atherosclerosis at the root of coronary heart disease, let alone to treat myocardiar 200044 ischemia and hypoxia or myocardial necrosis caused by stenosis or obstruction. Therefore, interventional therapy “stent placement” and coronary artery bypass graft treatment methods have emerged. “Stent placement” is a temporary treatment for dredging blood vessels by clinical physical methods, which cannot prolong the life of patients, and may cause other coronary arteries to accelerate the development of atherosclerosis, and must be treated with antithrombotic drugs for a long time, which has huge side effects.
[0009] In order to solve the above-mentioned problems in the existing technology, the invention offers a drug composition with good safety, good curative effect and basically no side effect, and its preparation method and application. The drug composition can effectively metabolize the atherosclerosis formed in coronary artery stenosis of coronary heart disease, and can obtain imaging improvement.
[0010] The technical scheme of the present invention is:
[0011] The raw material components of the drug composition for the treatment of coronary artery stenosis of coronary heart disease include:
[0012] L-methyl folate salt7.5-15 parts by weight, coenzyme Q10 150-300 parts by weight, methyl vitamin B122-4 parts by weight, arginine 100-200 parts by weight, magnesium oxide 100-200 parts by weight share.
[0013] The raw material components of the further optimized the pharmaceutical composition for the treatment of coronary artery stenosis in coronary heart disease include:
[0014] 8-10 parts by weight of L-methyl folate salt, 180-260 parts by weight of coenzyme Q10,
122.5-3.5 parts by weight of methyl vitamin B, 120-180 parts by weight of arginine, 120-180 parts by weight of magnesium oxide 180 parts by weight.
[0015] The raw material components of the further optimized the pharmaceutical composition for the treatment of coronary artery stenosis in coronary heart disease include:
[0016] 8 parts by weight of L-methyl folate salt, 200 parts by weight of coenzyme Q10, 3 parts by weight of methyl vitamin B12, 150 parts by weight of arginine, and 150 parts by weight of magnesium oxide.
[0017] The formulation of the pharmaceutical composition is powder, pill, tablet or capsule.
[0018] A method for preparing the pharmaceutical composition for the treatment of coronary artery stenosis of coronary heart disease includes the following steps:
[0019] (1) Weigh L-methyl folate salt, coenzyme Q10, and methyl vitamin B12 respectively, and mix under stirring conditions to obtain a mixture A;
[0020] (2) Weigh arginine and magnesium oxide, and mix them under stirring conditions to obtain a mixture B; 3
[0021] (3) Mix mixture A and mixture B uniformly to obtain the pharmaceutical composition for treating coronary artery stenosis of coronary heart disease. LUS00644
[0022] In step (1), the stirring speed is 1000-2000 rpm, and the stirring time is 10-20 min
[0023] In step (2), the stirring speed is 1000-2000 rpm, and the stirring time is 10-20 min.
[0024] In step (3), the particle size of the pharmaceutical composition is 300-500 mesh.
[0025] In step (3), the particle size of the pharmaceutical composition is 400 mesh.
[0026] The application of any of the pharmaceutical composition in preparation of drugs for coronary artery stenosis of coronary heart disease.
[0027] In order to facilitate the understanding of the invention, the bulk drug and drug effect of the invention are further elaborated.
[0028] L-methyl folate salt can enter the human body to obtain L-methyl folate, which is the only active form of folic acid that can pass through the blood-brain barrier. On the one hand, L-methyl folate is a NO synthase cofactor, which controls the synthesis of NO by affecting the activity of NO synthase, and then affects the function of vascular endothelial cells. On the other hand, L- methyl folate takes parts in the mutual conversion of amino acids, converting homocysteine to methionine to eliminate the accumulation of homocysteine to form homocysteine, thus eliminating the damaging effect of high homocysteine on vascular endothelial cells to eliminate obstacles of NO synthesis and release.
[0029] Coenzyme Q10 is a kind of fat-soluble quinone compound which exists in nature and its structure is similar to vitamin K, vitamin E and quinone. It is involved in energy production and activation in human body cells and is the most effective antioxidant component to prevent the formation of atherosclerosis. At the age of 20, the ability of self-synthesized coenzyme Q10 reaches the peak and maintains at about 50 years old. Then it will decrease year by year, because the mitochondrial DNA material stored in coenzyme Q10 is destroyed by oxygen free radicals, resulting in the reduction of independent synthesis of coenzyme Q10. As a result, the metabolic function of human cells, especially heart cells, decreases. The physiological process of coenzyme Q10 is similar to that of NO synthesis by endothelial cells. At the age of 20, the synthesis of NO in endothelial cells reaches the peak, and then the vascular function reaches the best state. After that, the synthesis of NO in endothelial cells decreases gradually. At the age of 60, the function of endothelial cells is only about 15 % of the peak. Coenzyme Q10 helps to provide sufficient oxygen for myocardium and prevent sudden heart disease, and it especially plays a vital role during myocardial hypoxia. Since most patients with cardiovascular and cerebrovascular diseases take statins in large quantities, statins inhibit cholesterol synthesis and lipid-lowering, and also inhibit the production of coenzyme Q10 in the body. Middle-aged and elderly patients are more likely to have insufficient coenzyme Q10 in the body. Therefore, the patients must supplement coenzyme Q10 at the same time when using statins.
[0030] Methyl vitamin B12 is one of two bioactive vitamin B12. Methyl vitamin B12 is the main form of circulating vitamin B12, which is transported to peripheral tissues in this form. Vitamin B12 4 plays a vital role in maintaining the normal function of the nervous system and it is also involved in the physiological process related to B12. Vitamin B12 deficiency can cause anemia, mental 200644 retardation, nervous system dysfunction and other diseases. Aging and many diseases can lead to vitamin B12 activation disorders, causing cardiovascular and cerebrovascular diseases.
[0031] Arginine, a semi-essential amino acid, is the direct precursor for NO synthesis. It is a biologically active substance necessary to maintain the normal function of the nervous system and blood circulation, and it will be increasingly scarce with age.
[0032] Magnesium oxide enhances the activity of various enzymes in heart organs, helps blood circulation and relieves nerves, maintains normal muscle (including myocardium) and nerve activity and reduces calcification in soft tissues (including myocardium).
[0033] The beneficial effect of the invention is:
[0034] The pharmaceutical composition for the treatment of coronary artery stenosis of coronary heart disease described in the present invention adopts L- methyl folate salt, coenzyme Q10, methyl vitamin B12, arginine, and magnesium oxide as raw materials for formulation and supplemented by appropriate dose ratio. Among them, L- methyl folate salt and arginine correct and improve the function of vascular endothelial cells by regulating the synthesis and release of NO in vascular endothelial cells. Magnesium ion provided by magnesium oxide is an activator of NO synthase in a variety of vascular endothelial cells, which regulates the synthesis of NO in vascular endothelial cells by activating neuronal nitric oxide synthase (nNOS), endothelial nitric oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS ) induced by injury. In addition, magnesium ions have the effect of blocking the outward current of potassium ion channels, and regulating the balance of myocardial potassium by preventing the outflow of potassium ions to avoid heart failure caused by low potassium. Meanwhile, magnesium ion, as a calcium blocker, can have the effect of inhibiting calcium channels and avoid excessive “calcium repair’ caused by inflammatory factors leading to vascular blockage and vascular calcification. Coenzyme Q10 has the effect of activating inducible nitric oxide synthase (iNOS), acting on cardiac atherosclerosis or directly reacting with peroxide free radicals through anti-lipid peroxidation, while regulating cardiac energy metabolism to maintain myocardial activity. The final prepared pharmaceutical composition for the treatment of coronary artery stenosis of coronary heart disease, with the synergistic effect of various raw material components, plays a joint role in improving the function of vascular endothelial cells, eliminating the inflammatory factors of myocardial cells, and improving myocardial viability. It effectively metabolizes the formed atherosclerosis, dissolves thrombus by thrombolysis, and directly acts on the lesion, thus achieving the purpose of reversing coronary artery stenosis of coronary heart disease. The invention overcomes the defect that the prior technique cannot obtain the imaging improvement effect, thus well achieving the lesion reversal and a good prognosis.
[0035] FIG. 1 shows the CTA scan of a patient before treatment in a typical case 1 of the clinical 900644 trial of the invention;
[0036] FIG. 2 shows the CTA scan of a patient after treatment in a typical case 1 of the clinical trial of the invention;
[0037] 1-Calcification point; 2-right coronary artery.
[0038] The invention is further illustrated below by specific embodiments.
[0039] Example 1
[0040] This embodiment provides a pharmaceutical composition for treating coronary artery of coronary heart disease, and the raw material components include:
[0041] L-Calcium methyl folate 7.5mg Coenzyme Q10 150mg Methyl vitamins B12 2mg Arginine 100mg Magnesium Oxide 100mg
[0042] Further, provide a method for preparing the drug for coronary stenosis of coronary heart disease, including the following steps:
[0043] (1) Weigh L-methyl folate calcium, coenzyme Q10, and methyl vitamin B12 respectively, and stir them at a stirring speed of 1000 rpm for 20 min to obtain mixture A;
[0044] (2) Weigh arginine and magnesium oxide, and stir them at a stirring speed of 1000 rpm for min to obtain mixture B;
[0045] (3) Mix the mixture A and the mixture B uniformly to obtain a pharmaceutical composition for the treatment of coronary artery stenosis with a particle diameter of 300 nm.
[0046] (4) Add conventional adjuvants to the pharmaceutical composition for treating coronary artery stenosis of coronary heart disease described in step (3), and prepare a capsule according to a conventional process.
[0047] Example 2
[0048] The embodiment provides a pharmaceutical composition for the treatment of coronary artery stenosis of coronary heart disease. The raw materials include:
[0049] L-Magnesium Methyl folate 8mg Coenzyme Q10 180mg Methyl vitamins B12 2.5mg Arginine 120mg Magnesium Oxide 120mg 6
[0050] Further, provide a method for preparing the drug for coronary stenosis of coronary heart disease, including the following steps: LUS00644
[0051] (1) Weigh L-methyl magnesium folate, coenzyme Q10, and methyl vitamin B12 respectively, and stir them at a stirring speed of 1000 rpm for 20 min to obtain mixture A;
[0052] (2) Weigh arginine and magnesium oxide, and stir them at a stirring speed of 2000 rpm for min to obtain mixture B;
[0053] (3) Mix the mixture A and the mixture B uniformly to obtain a pharmaceutical composition for the treatment of coronary artery stenosis of coronary heart disease with a particle diameter of 300 nm.
[0054] (4) Add conventional adjuvants to the pharmaceutical composition for treating coronary artery stenosis of coronary heart disease described in step (3), and prepare powders according to conventional techniques.
[0055] Example 3
[0056] This embodiment provides a pharmaceutical composition for the treatment of coronary artery stenosis of coronary heart disease; the raw material components include:
[0057] L- Calcium methyl folate 15mg Coenzyme Q10 300mg Methyl vitamins B12 4mg Arginine 200mg Magnesium Oxide 200mg
[0058] Further, it provides a method for preparing the drug for coronary stenosis of coronary heart disease, including the following steps:
[0059] (1) Weigh L-methyl folate calcium, coenzyme Q10, and methyl vitamin B12 respectively, and stir them at a stirring speed of 1000 rpm for 20 min to prepare a mixture A;
[0060] (2) Weigh arginine and magnesium oxide, and stir them at a stirring speed of 2000 rpm for 10 min to obtain a mixture B;
[0061] (3) Mix the mixture A and the mixture B uniformly to obtain a pharmaceutical composition for treating coronary artery stenosis of coronary heart disease with a particle diameter of 500 nm.
[0062] (4) Add conventional adjuvants to the pharmaceutical composition for treating coronary artery stenosis of coronary heart disease described in step (3), and prepare a pill according to a conventional process.
[0063] Example 4
[0064] This embodiment provides a pharmaceutical composition for the treatment of coronary artery stenosis of coronary heart disease; the raw material components include:
[0065] L- Magnesium Methyl folate 10mg Coenzyme Q10 260mg 7
Methyl vitamins B12 3.5mg Arginine 180mg LUS00644 Magnesium Oxide 180mg
[0066] Further, provide a method for preparing the drug for coronary stenosis of coronary heart disease, including the following steps:
[0067] (1) Weigh L-methyl magnesium folate, coenzyme Q10, and methyl vitamin B12 respectively, and stir them at a stirring speed of 1000 rpm for 18 min to obtain a mixture A;
[0068] (2) Weigh arginine and magnesium oxide, and stir them at a stirring speed of 1000 rpm for 18 minutes to obtain a mixture B;
[0069] (3) Mix the mixture A and the mixture B uniformly to obtain a pharmaceutical composition for the treatment of coronary artery stenosis with a particle size of 400 nm.
[0070] (4) Add conventional excipients to the pharmaceutical composition for treating coronary artery stenosis of coronary heart disease described in step (3), and prepare tablets according to conventional techniques.
[0071] Example 5
[0072] This embodiment provides a pharmaceutical composition for the treatment of coronary artery stenosis of coronary heart disease, and the raw material components include:
[0073] L- Calcium Methyl folate 8mg Coenzyme Q10 200mg Methyl vitamins B12 3mg Arginine 150mg Magnesium Oxide 150mg
[0074] Further, provide a method for preparing the drug for coronary stenosis of coronary heart disease, including the following steps:
[0075] (1) Weigh L-methyl folate calcium, coenzyme Q10, and methyl vitamin B12 respectively, and stir them at a stirring speed of 2000 rpm for 15 min to prepare a mixture A;
[0076] (2) Weigh arginine and magnesium oxide, and stir them at a stirring speed of 2000 rpm for mins to obtain a mixture B;
[0077] (3) Mix the mixture A and the mixture B uniformly to obtain a pharmaceutical composition for the treatment of coronary artery stenosis with a particle diameter of 400 nm.
[0078] (4) Add conventional adjuvants to the pharmaceutical composition for treating coronary artery stenosis of coronary heart disease described in step (3), and prepare a capsule according to a conventional process.
[0079] Clinical trial example
[0080] I. Clinical data: From June 2012 to now, 68 patients with coronary artery stenosis and 18 patients with carotid artery plaque were clinically screened for efficacy study. Among the patients with coronary artery stenosis, 35 cases with severe stenosis and 15 cases with moderate stenosis. 8
[0081] Il. Judgment of curative effect:
[0082] Significantly effective: coronary stenosis is reversed more than one level (20 %). LUS00644
[0083] Effective: stenosis is improved, symptoms are relieved.
[0084] The effect is not obvious or ineffective: the symptoms are not relieved or improved.
[0085] Ill. Clinical trial results: 50 cases of coronary artery stenosis are significantly effective in the treatment of coronary heart disease, accounting for 73.5%; 5 cases are effective, accounting for 7.4%; 13 cases are ineffective, accounting for 19.1%, and the total effective rate is 80 .9%. In the treatment of carotid plaque, 12 cases are significantly effective, 66.7%; 3 cases are effective, accounting for 16.6%, and 3 cases are ineffective, accounting for 16.7%; the total effective rate is 83.3%.
[0086] IV. Typical cases
[0087] Typical Case 1:
[0088] Li, male, 42 years old. On November 17, 2016, due to a sudden cardiac discomfort, he went to a third-class hospital in a central hospital, the hospital's CTA scan showed that there were more shadows around the calcification point of the right coronary artery (see Figure 1), and the vascular lumen was narrowed by about 90%, which was a severe stenosis. The hospital recommended doing radiograph and putting the stent for him. Li considered that he was still young and the stent might cause permanent damage to the heart. He disagreed with the hospital's recommendation and was discharged. After consultation, he agreed to take the capsules of the drug composition of the present invention, and stop taking any other drugs. After taking the drug composition for 16 days, the heart discomfort symptoms were basically relieved. One month later, he felt quite good. He went to the same hospital for a follow-up visit after 5 months. The CTA scan showed that the shadowed part around the calcification point of the right coronary artery was metabolized and disappeared (see Figure 2). The stenosis was about 50%, belonging to moderate stenosis, which was better than before.
[0089] CTA detection report content:
[0090] On Nov. 17”, 2016, CTA observations and impressions of coronary arteries and heart: calcified plagues are seen in the trunk of left coronary artery, and local lumen is slightly narrow; low-density plaque is observed in the proximal segment of left anterior descending branch, and local lumen is slightly narrow; there is no obvious abnormality in the left circumflex. Mixed density plaques are observed in the proximal segment of the right coronary artery, and local lumen is severely narrow. Diagnosis opinions: 1. Left main coronary artery calcified plaques are formed, and local lumen is slightly narrow. 2. The left anterior descending branch of proximal low-density plaques are formed, and local lumen is slightly narrow. 3. The right coronary artery proximal mixed density plaques are formed, and local lumen is slightly narrow.
[0091] On May. 5, 2017, CTA findings and impressions of coronary artery and cardiac: the main left coronary artery is not abnormal, mixed-density plaque formation is seen on the wall of the beginning of the left anterior descending branch, and the corresponding lumen stenosis is about 9
40%; There are no obvious abnormalities in the remaining segments and main branches; no obvious abnormalities in the left circumflex branch; mixed-density plagues are formed on the wal 200644 of the proximal right coronary artery, and the corresponding lumen stenosis degree is about 50%, compared with the film on November 17, 2016 , which is smaller than before; no obvious abnormalities in the remaining sections. Diagnosis opinions: 1. Mixed plaques are formed on the wall at the beginning of the left anterior descending branch, and the corresponding lumen is slightly narrowed; 2. Mixed-density plaques are formed on the proximal wall of the right coronary artery, and the corresponding lumen is moderately narrowed, which is better than before, please combine with clinical.
[0092] Typical Case 2:
[0093] Wei XX, male, 54 years old. His coronary heart disease was serious. A CTA scan of Dec. 2nd, 2016 in a medical school shows that diffuse calcification and non-calcified plague formation were seen in the proximal left circumflex artery, resulting in severe narrowing of the corresponding lumen, discontinuous filling of local contrast media, and poor distal filing; The hospital recommended to put at least 3 stents for him. Because of his serious condition, it was difficult for him to go upstairs, and he even dare not “tilt the waist”, which would cause dizziness; walking one or two hundred meters makes him feel very uncomfortable. It was suggested to treat him with the pharmaceutical composition of the present invention. After 7 days, the symptoms wer relieved, and drugs such as Plavix and aspirin were stopped. Taking into account the patient's severe hypertension, the drugs cannot be stopped immediately. The hypertension drugs and blood lipid- lowering drugs were slowly reduced. After 2 months, the discomfort was basically eliminated. After months, a CTA scan in a third-class hospital of a central hospital shows that multiple soft plaques and mixed plaque formation were seen in the left circumflex branch; the corresponding lumen had different degrees of narrowing, and the severe stenosis disappeared.
[0094] CTA detection report content:
[0095] On Dec. 2", 2016, Clinical diagnosis: coronary atherosclerotic coronary heart disease. In the proximal segment of the left anterior descending coronary artery, localized mixed plaques are observed, with mainly calcified components, resulting in mild stenosis of the corresponding lumen; In the proximal segment of the second diagonal branch, localized non-calcifying plaques are observed, resulting in slight narrowing of the corresponding lumen; Diffuse calcification and non- calcification plaque formation are seen in the proximal part of the left circumflex branch, resulting in severe narrowing of the corresponding lumen, discontinuous filling of local contrast media, and poor distal filling; The middle branch and pure marginal branch are slender. Diffuse calcification and non-calcification plaque formation are seen in the right coronary artery. Diagnosis opinions:
1. Based on the CTA manifestations of left circumflex plaque formation and subtotal occlusion, DSA testing is recommended; 2. It is consistent with the CTA manifestation of multiple coronary plaque formation and luminal stenosis.
[0096] On May. 12", 2017, CTA findings and impressions of coronary artery and heart: there is no abnormality in the trunk of left coronary artery, localized mixed plaques are observed in the proximal segment of left anterior descending artery, and corresponding lumen has mild [0500644 moderate stenosis. Multiple soft plaques and mixed plaques are seen in the left circumflex branch and the corresponding lumen has different degrees of narrowing; Multiple soft plaques and mixed plaques are observed in the right coronary artery, and the corresponding lumen has different degrees of narrowing. Diagnosis opinions: 1. Mixed plague formation are seen in the proximal segment of left anterior descending branch, and the corresponding lumen has mild to moderate stenosis. 2. Multiple soft plaques and mixed plaques are seen in the left circumflex branch and the corresponding lumen has different degrees of narrowing. 3. Multiple soft plaques and mixed plaques are observed in the right coronary artery, and the corresponding lumen has different degrees of narrowing.
[0097] The contents mentioned above are only the specific embodiments of the invention, but the protection scope of the invention is not limited to this. And any technical person familiar with the technical field who can easily think of changes or replacements within the technical scope disclosed by the invention shall be covered by the protection scope of the invention. Therefore, the protection scope of the invention should be subject to the protection scope of the claims.
11
Claims (10)
- CLAIMS LU5006441. The feature of the pharmaceutical composition for treating coronary artery stenosis of coronary heart disease is that the raw material components include:7.5-15 parts by weight of L-methyl folate salt, 150-300 parts by weight coenzyme Q10, 2-4 parts by weight of methyl vitamin B12, 100-200 parts by weight of arginine, and 100-200 parts by weight of magnesium oxide.2. According to the drug composition for treating coronary artery stenosis of coronary heart disease described in claim 1, its features are that the raw material components include: 8-10 parts by weight of L-methyl folate salt, 180-260 parts by weight of coenzyme Q10, 122.5-3.5 parts by weight of methyl vitamin B, 120-180 parts by weight of arginine, 120-180 parts by weight of magnesium oxide.3. According to the drug composition for treating coronary artery stenosis of coronary heart disease described in claim 1, its features are that the raw material composition includes: 8 parts by weight of L-methyl folate salt, 200 parts by weight of coenzyme Q10, 3 parts by weight of methyl vitamin B12, 150 parts by weight of arginine, and 150 parts by weight of magnesium oxide.4. According to the claim 1-3 any of the pharmaceutical composition for treating coronary artery stenosis of coronary heart disease, its features are that the dosage form of the pharmaceutical composition is powder, pill, tablet or capsule.5. A method for preparing the pharmaceutical composition for treating coronary artery stenosis in coronary heart disease described in any of the requirements 1-4 consists of below steps: (1) Weigh L-methyl folate salt, coenzyme Q10, and methyl vitamin B12 respectively, and mix under stirring conditions to obtain mixture A; 2) Weigh arginine and magnesium oxide, and mix them under stirring conditions to obtain mixture B; 12L 44 (3) Mix the mixture A and the mixture B uniformly to obtain the the pharmaceutical 5006 composition for treating coronary artery stenosis of coronary heart disease.6. According to the method described in claim 5 for the preparation of the pharmaceutical composition for treating coronary artery stenosis of coronary heart disease, the feature is that in step (1), the stirring speed is 1000 — 2000 rpm, and the stirring time is 10 — 20 min.7. According to the method described in claim 5 for the preparation of the pharmaceutical composition for treating coronary artery stenosis of coronary heart disease, the feature is that in step (2), the stirring speed is 1000 — 2000 rpm, and the stirring time is 10 — 20 min.8. According to the preparation method of drug composition described in claim 5, its feature is that in step (3), the particle size of the drug composition is 300 — 500 meshes.9. According to the method of preparing the pharmaceutical composition described in claim 8, the feature is that the particle size of the pharmaceutical composition is 400 mesh.10. Application of any of the pharmaceutical composition described in claim 1-4 in preparation of drugs for treating coronary stenosis of coronary heart disease.13
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU500644A LU500644B1 (en) | 2021-09-10 | 2021-09-10 | Drug combination, preparation and application for treating coronary heart disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU500644A LU500644B1 (en) | 2021-09-10 | 2021-09-10 | Drug combination, preparation and application for treating coronary heart disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU500644B1 true LU500644B1 (en) | 2022-05-02 |
Family
ID=81389356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU500644A LU500644B1 (en) | 2021-09-10 | 2021-09-10 | Drug combination, preparation and application for treating coronary heart disease |
Country Status (1)
| Country | Link |
|---|---|
| LU (1) | LU500644B1 (en) |
-
2021
- 2021-09-10 LU LU500644A patent/LU500644B1/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yeom et al. | Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration | |
| US7244749B2 (en) | Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases | |
| US6953588B2 (en) | Multi-vitamin and mineral supplement | |
| JP2018131469A (en) | Methods of treating or ameliorating diseases and enhancing performance comprising use of magnetic dipole stabilized solution | |
| HANDFIELD‐JONES et al. | High dose nicotinamide in the treatment of necrobiosis lipoidica | |
| US9849157B2 (en) | Cardiovascular therapy compositions | |
| US9168308B2 (en) | Compositions and methods for nutritional supplementation | |
| Gaby | Nutritional treatments for acute myocardial infarction | |
| WO1993013660A1 (en) | Pharmaceutically active antioxydant containing composition and the method of its use to prevent and treat restenosis following angioplasty | |
| JP2007504182A (en) | Compositions and methods for promoting bone healing | |
| Petronek et al. | Utilization of redox modulating small molecules that selectively act as pro-oxidants in cancer cells to open a therapeutic window for improving cancer therapy | |
| US6805880B1 (en) | Pharmaceutical delivery system for vitamin C and vitamin E and use of a combination of vitamin C and E for preventing or treating conditions involving oxidative stress | |
| Luo et al. | Biomaterial-mediated targeted therapeutics of myocardial ischemia-reperfusion injury | |
| US5712259A (en) | NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome | |
| LU500644B1 (en) | Drug combination, preparation and application for treating coronary heart disease | |
| CA2609626A1 (en) | Composition comprising l-arginine, crataegus, artichoke flavonoids and citruilline for improving blood flow in working muscles | |
| US7649017B2 (en) | Compositions intended for the treatment of peripheral neuropathies, preparation thereof and uses of same | |
| FR2641189A1 (en) | Pharmaceutical compositions containing acetylsalicylic acid and vitamin B6 | |
| CA2291959A1 (en) | A nutriceutical composition of l-carnitine, ubiquinone, n-3 polyunsaturated fatty acids and vitamins specifically formulated at pharmacological doses for the amelioration of the risk factors and symptoms of atherosclerosis-related illnesses | |
| CN108714153A (en) | Treat pharmaceutical composition, preparation method and the application of coronary heart disease coronary stenosis | |
| JP2005522485A (en) | Methods for reducing calcified arterial plaque accumulation and cell dysfunction and balancing ionic calcium | |
| RU2228746C1 (en) | Antihyperlipidemic agent (variants) | |
| US11529383B2 (en) | Biochemical scaffolds for modulating cell function | |
| US10004757B1 (en) | Oral supplement | |
| Xie et al. | Sickle cell anemia: the impact of discovery, politics, and business |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Effective date: 20220502 |